SCHEMBL13249174

SCHEMBL13249174

CC(=O)c1ccc(-c2ccc(Nc3nc4ccc(F)cc4s3)c(F)c2)cc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.59
MAPT P10636 8/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
NPC1 O15118 6/20 0.56
HPGD P15428 5/20 0.56
KDM4E B2RXH2 5/20 0.56
MEN1 O00255 5/20 0.56
HTT P42858 5/20 0.56
KMT2A Q03164 5/20 0.56
LMNA P02545 5/20 0.56
ALDH1A1 P00352 5/20 0.56
RAB9A P51151 5/20 0.56
NPSR1 Q6W5P4 3/20 0.56
TP53 P04637 2/20 0.56
USP2 O75604 1/20 0.56
CASP1 P29466 1/20 0.56
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1761329 0.92 DGAT1 (0.61) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL1761642 0.90 MAPT (0.61) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL1761458 0.85 DGAT1 (0.63) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL1761741 0.85 DGAT1 (0.55) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL12593941 0.84 MAPT (0.61) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL1761363 0.84 DGAT1 (0.66) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL1761436 0.83 DGAT1 (0.71) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL1761400 0.82 MAPT (0.71) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL3388733 0.82 DGAT1 (0.67) DGAT1MAPTSMN1; SMN2NPC1HPGD
SCHEMBL3388727 0.82 DGAT1 (0.67) DGAT1MAPTSMN1; SMN2NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759376-B2 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity BAYER HEALTHCARE LLC (US) 2010-07-20 US disclosed
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity FABP4, GPR119, PGC DGAT1 486/4885MAPT 3560/4885SMN1; SMN2 4216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.